My Account Log in

1 option

A Cost/Benefit Analysis of Clinical Trial Designs for COVID-19 Vaccine Candidates / Donald A. Berry, Scott Berry, Peter Hale, Leah Isakov, Andrew W. Lo, Kien Wei Siah, Chi Heem Wong.

NBER Working papers Available online

View online
Format:
Book
Author/Creator:
Berry, Donald A.
Contributor:
National Bureau of Economic Research.
Berry, Scott.
Hale, Peter.
Isakov, Leah.
Lo, Andrew W.
Siah, Kien Wei.
Wong, Chi Heem.
Series:
Working Paper Series (National Bureau of Economic Research) no. w27882.
NBER working paper series no. w27882
Language:
English
Physical Description:
1 online resource: illustrations (black and white);
Place of Publication:
Cambridge, Mass. National Bureau of Economic Research 2020.
Summary:
We compare and contrast the expected duration and number of infections and deaths averted among several designs for clinical trials of COVID-19 vaccine candidates, including traditional randomized clinical trials and adaptive and human challenge trials. Using epidemiological models calibrated to the current pandemic, we simulate the time course of each clinical trial design for 504 unique combinations of parameters, allowing us to determine which trial design is most effective for a given scenario. A human challenge trial provides maximal net benefits--averting an additional 1.1M infections and 8,000 deaths in the U.S. compared to the next best clinical trial design--if its set-up time is short or the pandemic spreads slowly. In most of the other cases, an adaptive trial provides greater net benefits.
Notes:
Print version record
October 2020.

The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.

Find

Home Release notes

My Account

Shelf Request an item Bookmarks Fines and fees Settings

Guides

Using the Find catalog Using Articles+ Using your account